CURATIS N AG

SW:CURN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$134.46 Million
CHF123.13 Million CHF
Market Cap Rank
#38786 Global
#134 in Switzerland
Share Price
CHF23.90
Change (1 day)
+0.00%
52-Week Range
CHF9.72 - CHF26.00
All Time High
CHF891.52
About

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more

CURATIS N AG (CURN) - Total Assets

Latest total assets as of June 2025: CHF54.52 Million CHF

Based on the latest financial reports, CURATIS N AG (CURN) holds total assets worth CHF54.52 Million CHF as of June 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

CURATIS N AG - Total Assets Trend (2002–2024)

This chart illustrates how CURATIS N AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

CURATIS N AG - Asset Composition Analysis

Current Asset Composition (December 2024)

CURATIS N AG's total assets of CHF54.52 Million consist of 10.6% current assets and 89.4% non-current assets.

Asset Category Amount (CHF) % of Total Assets
Cash & Equivalents CHF3.01 Million 5.4%
Accounts Receivable CHF1.56 Million 2.8%
Inventory CHF1.32 Million 2.4%
Property, Plant & Equipment CHF0.00 0.0%
Intangible Assets CHF49.38 Million 88.9%
Goodwill CHF0.00 0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how CURATIS N AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: CURATIS N AG's current assets represent 10.6% of total assets in 2024, a decrease from 36.2% in 2002.
  • Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 6.5% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 3.0% in 2002.
  • Asset Diversification: The largest asset category is intangible assets at 88.9% of total assets.

CURATIS N AG Competitors by Total Assets

Key competitors of CURATIS N AG based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
USA $67.26 Billion
Dongwha Pharm.Co.Ltd
KO:000020
Korea ₩654.63 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥27.28 Billion
Yuhan Corp Preferred
KO:000105
Korea ₩3.05 Trillion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥4.97 Billion
Kotra Industries Bhd
KLSE:0002
Malaysia RM363.90 Million
Yuyu Pharma
KO:000220
Korea ₩202.42 Billion
Ildong Holdings Co Ltd
KO:000230
Korea ₩813.62 Billion

CURATIS N AG - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.00 - 32.35

Lower asset utilization - CURATIS N AG generates 0.12x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -247.27% - 100.74%

Negative ROA - CURATIS N AG is currently not profitable relative to its asset base.

CURATIS N AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.50 0.92 1.09
Quick Ratio 1.07 0.72 1.09
Cash Ratio 0.62 0.51 0.00
Working Capital CHF1.65 Million CHF -555.00K CHF 17.00K

CURATIS N AG - Advanced Valuation Insights

This section examines the relationship between CURATIS N AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.06
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 46180.0%
Total Assets CHF55.54 Million
Market Capitalization $259.11K USD

Valuation Analysis

Below Book Valuation: The market values CURATIS N AG's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: CURATIS N AG's assets grew by 46180.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for CURATIS N AG (2002–2024)

The table below shows the annual total assets of CURATIS N AG from 2002 to 2024.

Year Total Assets Change
2024-12-31 CHF55.54 Million +46180.00%
2023-12-31 CHF120.00K -99.15%
2022-12-31 CHF14.05 Million +10227.94%
2021-12-31 CHF136.00K +7.09%
2020-12-31 CHF127.00K -94.16%
2019-12-31 CHF2.17 Million -0.73%
2018-12-31 CHF2.19 Million -67.24%
2017-12-31 CHF6.68 Million -5.70%
2016-12-31 CHF7.09 Million -11.01%
2015-12-31 CHF7.97 Million -19.95%
2014-12-31 CHF9.95 Million -14.75%
2013-12-31 CHF11.67 Million -39.27%
2012-12-31 CHF19.22 Million +56.62%
2011-12-31 CHF12.27 Million -8.15%
2010-12-31 CHF13.36 Million +61.52%
2009-12-31 CHF8.27 Million +62.45%
2008-12-31 CHF5.09 Million -45.61%
2007-12-31 CHF9.36 Million -32.69%
2006-12-31 CHF13.91 Million -59.87%
2005-12-31 CHF34.66 Million -41.97%
2004-12-31 CHF59.73 Million -16.27%
2003-12-31 CHF71.33 Million +3.32%
2002-12-31 CHF69.04 Million --